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Inactivations of DNA repair genes, O
6-methylguanine-DNA methyltransferase (MGMT) and hMLH1, by promoter hypermethylation
have been reported in several types of primary human neoplasia. This epigenetic inactivation mechanism remains elusive in
hepatocellular carcinoma (HCC). To investigate the relation between the expression of MGMT and hMLH1 and the CpG methylation
within their promoters in HCCs with or without hepatitis viral infection, we performed immunohistochemistry and urea/bisulphite
sequencing on 46 HCCs, corresponding noncancerous tissues, and 20 normal liver tissues. MGMT- and hMLH1-negative HCCs were
60.9% (28 out of 46) and 21.8% (10 out of 46), respectively. HCCs lacking both proteins were 10.9% (five out of 46). The frequency
and extent of CpG methylation in the MGMT promoter increased along with hepatitis viral infection and pathological progression.
MGMT-negative tumours showed very frequent and widespread methylation in the promoter compared with MGMT-positive
tumours. Half of the hMLH1-negative HCCs showed promoter hypermethylation. These data suggested that MGMT gene silencing in
a subset of HCCs was likely caused by epigenetic alteration, such as promoter hypermethylation, and that the promoter
hypermethylation silenced the hMLH1 gene in half of the hMLH1-negative tumours. A correlation between the promoter
methylation status and viral infection, although it was weak, intimated that hepatitis viral infections could play a role in the CpG
methylation of the MGMT promoter.
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Hepatocellular carcinoma (HCC) is one of the most frequent
human malignancies and a major cause of cancer-related deaths
worldwide (Okuda et al, 1992). Most HCCs exhibit characteristics
compatible with chronic hepatitis and cirrhosis caused by
persistent infection of hepatitis B virus (HBV) and/or hepatitis C
virus (HCV) (Okuda et al, 1992). Both chronic hepatitis and
cirrhosis associated with viral infection are considered as
precancerous conditions (Paradis et al, 1998). The process of
chronic inflammation or cirrhosis initiates clonal expansion and
facilitates regeneration of hepatocytes (Aihara et al, 1994). During
neoplastic degenerative change, an accumulation of genetic
alterations or epigenetic changes may occur. However, the
molecular mechanisms of hepatocarcinogenesis associated with
hepatitis viral infection have not been clarified.
O
6-methylguanine-DNA methyltransferase (MGMT) is a DNA
repair enzyme that plays an important role in the defence against
the carcinogenic and cytotoxic effects of alkylating agents in
cellular DNA (Pegg, 1990). Since ubiquitous and environmental
alkylating agents such as N-nitroso compounds are principally
metabolised and activated in mammalian hepatocytes, liver tissue
is persistently exposed to activated alkylating agents (Gerson et al,
1986). It was demonstrated that Mgmt-targeted mice (Mgmt
 / )
treated with alkylating agents generated hepatocellular carcinoma
(Iwakuma et al, 1997). Major and Collier (1998) suggested that
MGMT protein activity decreased in chronic hepatitis, cirrhosis,
and HCCs. We have recently reported that the MGMT expression
was frequently lost in a variety of human tumours and was a
significant prognostic factor (Matsukura et al, 2001). Since loss of
MGMT expression was not commonly because of a genetic change,
it has been suggested that another cause, such as epigenetic
change, is involved (Esteller et al, 1999; Bhakat and Mitra, 2000).
Mismatch repair system (MMR) is an essential system by which
cells correct errors in DNA replication during proliferation to
maintain the fidelity of the genome (Lahue et al, 1989). One of the
MMR genes, hMLH1, has been demonstrated to play a pivotal role
in DNA MMR (Papadopoulos et al, 1994). In addition, the
important association between MGMT and MMR in DNA
repair was pointed out by Frayling (1999). Furthermore,
it was shown that Mgmt
 /  Mlh1
 /  (double knockout) mice
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yTable 1 Primer sequence and PCR conditions
Primer sequences PCR cycles
MGMT
1st PCR
S1 TTGGAIGGTATIGTTATTATAGG 40 cycles of 951C/30 s, 501C/30 s, 721C/90 s
AS1 AATAAATAAAAATCAAAACIACCC
2nd PCR
S2 TTATTATAGGTTTTGGAGGTTGTTT 30 cycles of 951C/30 s, 601C/30 s, 721C/60 s
AS2 AAAAATCAAAACIACCCCCC
hMLH1
1st PCR
S1 GAIGTTTATATGTTIGGGTAGTAT 40 cycles of 951C/30 s, 501C/30 s, 721C/90 s
AS1 ACCACIAACIACATTTTAACICC
2nd PCR
S2 TTTTTATTTTAGTIGIGATTTTTTA 30 cycles of 951C/30 s, 521C/30 s, 721C/60 s
AS2 CAAAAAAACCAAAAAAACITCTAAA
Colony PCR
VS1 TCCGGCTCGTATGTTGTGTGGA 20 cycles of 961C/20 s, 601C/20 s, 721C/120s
VAS1 GTGCTGCAAGGCGATTAAGTTGG
I=inosine.
Figure 1 Immunohistochemical staining of MGMT (A, B) and hMLH1 (C, D) in HCCs. MGMT- or hMLH1-positive tumour cells showed strongly stained
nuclei (A, C), while no stained nucleus was detected in MGMT- or hMLH1-negative tumours (B, D), except for bile duct cells as an internal positive control.
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ytreated with alkylating agents exhibited high susceptibility to
carcinoma (Kawate et al, 1998). It is, however, unclear whether
tumours expressing neither of the genes exist in human
HCCs.
It has been proposed that aberrant DNA methylation of CpG
islands in the promoter region is correlated with inactivation of
tumour suppressor genes in human cancer. Esteller et al. (2001)
have demonstrated the reduced expression of tumour suppressor
genes such as p16, MGMT, and hMLH1 by promoter hypermethy-
lation in several human neoplasias, and have suggested that this
epigenetic change might be an early event in the pathogenesis of
several human tumours. Recently, the correlation of p16 promoter
hypermethylation with chronic hepatitis and cirrhosis associated
with HBV or HCV infection has been reported (Kaneto et al,
2001).
Here, we report the existence of human HCCs lacking both
MGMT and hMLH1 proteins, the relation between HCCs
associated with hepatitis viral infection and detailed CpG
methylation status of MGMT and hMLH1 promoter regions, and
the specific CpG methylation pattern of MGMT- and hMLH1-
negative tumours.
MATERIALS AND METHODS
Tissue specimens
A total of 46, HCCs and adjacent noncancerous liver tissues (mean
age 63.8 years; 35 males and 11 females; seven HBV positives, 33
HCV positives, one HBV/HCV positive and five HBV/HCV
Table 2 Background of patients with hepatocellular carcinomas
Clinical parameters Pathological parameters of tumours Immunohistochemistry
Case Age Sex Viral status Noncancerous liver tissue Differentiation (grade) Size (cm) MGMT hMLH1
1 62 M C CH I 5.5 – +
2 58 M B CH II 10.3 – +
3 73 F C CH II 6.3 – +
4 60 M B & C LC I 2.0 – +
5 62 F C LC III 2.8 – +
6 48 M B LC II 6.0 – +
7 51 M B LC I 4.5 – +
8 58 F C CH II 8.5 – –
9 67 M C CH III 2.1 – +
10 51 M NBNC N II 2.5 – –
11 68 M C LC II 2.0 – +
12 66 M C CH II 4.5 – –
13 72 M C LC II 10.5 – +
14 57 M B LC III 3.0 – +
15 67 M C CH II 2.0 – +
16 62 M NBNC N I 6.0 – +
17 65 M C LC II 2.4 – –
18 51 M C CH II 4.5 – +
19 54 M B LC III 4.3 – +
20 65 M C CH II 8.5 – +
21 73 M C LC II 3.0 – +
22 61 M C CH II 3.0 – +
23 59 M C LC I 3.5 – –
24 71 M C LC I 9.0 – +
25 68 M C CH II 2.5 – +
26 64 M C CH III 2.0 – +
27 74 M C CH I 7.0 – +
28 53 M NBNC N I 6.0 – +
29 72 F C LC II 2.8 + –
30 70 M NBNC N II 14.0 + +
31 63 M C CH II 3.2 + +
32 50 M B LC II 4.0 + +
33 60 F C LC I 2.5 + +
34 60 M NBNC N I 3.0 + –
35 70 M C CH II 4.0 + –
36 65 F C CH II 2.5 + –
37 70 F C CH II 4.2 + –
38 68 M C LC II 3.5 + +
39 73 F B CH II 3.0 + +
40 66 M C CH I 4.0 + +
41 62 M C LC II 3.6 + +
42 62 M C LC II 2.5 + +
43 69 F C CH II 8.5 + +
44 68 F C LC II 3.5 + +
45 70 F C CH II 2.0 + +
46 71 M C CH I 2.0 + +
Viral status B=HBs Ag positive; C=HCV antibody positive; NBNC=HBs Ag and HCV antibody negative; CH=chronic hepatitis; LC=liver cirrhosis; N=normal liver; grade I=well-
differentiated HCC; grade II=moderately differentiated HCC; grade III=poorly differentiated HCC; +=positive;  =negative.
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ynegatives) and 20 normal liver (mean age 59.9 years; 14 males and
six females) tissue specimens were obtained surgically and frozen
at  801C. All specimens were subjected to pathological diagnosis.
DNAs of all tumour samples were extracted from pathologically
obvious cancerous regions in the resected liver. HBV and HCV
infections were diagnosed serologically with HBs antigen (LPIA-
200; Diatron Laboratories, Tokyo, Japan) and anti-HCV antibody
(Immunocheck-HCV Ab; International Reagent, Kobe, Japan),
respectively. Informed consent was obtained from all patients.
Anti-MGMT antibody
Polyclonal rabbit antibodies against human MGMT protein were
prepared using TrpE fusion protein, as described (Nakabeppu and
Nathans, 1991). Escherichia coli BL21 (DE3) carrying pET3d:TrpE-
hMGMT-1 that encodes the TrpE polypeptide fused to a region of
MGMT (residues 1–45) at the C terminus was used to produce
each fusion protein (Studier et al, 1990), and polyclonal antibodies
against the fusion protein were raised in rabbits. The serum was
initially applied to a TrpE-hMGMT-1-coupled column; their bound
materials were eluted at pH 2.3 and dialysed against 10mM Tris-
HCl (pH 7.4) and 150mM NaCl. To increase antibody specificity,
the eluted fraction was applied to an affinity column with TrpE-
mMGMT-1, in which a corresponding region of mouse MGMT
(residues 1–58) was fused to TrpE (Kawate et al, 1995), as a ligand.
Then the bound fraction was eluted and dialysed. This fraction was
used as an anti-MGMT antibody. The specificity of the antibody
has been reported previously (Matsukura et al, 2001).
Immunohistochemistry
Immunohistochemical studies for MGMT (Matsukura et al, 2001)
and hMLH1 (Wang et al, 2001) were performed as described
previously. In the present study, mouse monoclonal antibody
against hMLH1 protein (clone G168-728; PharMingen, San Diego,
CA, USA) (Wang et al, 2001) was used. Positive staining was
identified by the presence of brown staining in the nucleus and/or
cytoplasm. MGMT and hMLH1 expression were evaluated as
positive if the distribution of stained cells was more than 10% of
cancer cells. The expression status of MGMT and hMLH1 was
assessed by two pathologists without a knowledge of the
clinicopathological features of the case or the clinical outcome.
Urea/bisulphite modification of DNA and PCR
amplification
The urea/bisulphite treatment of genomic DNA was performed as
described by Paulin et al (1998). The modified DNA was
Figure 2 CpG island of the MGMT and hMLH1 promoter region. (A) Schematic representation of the MGMT CpG island containing 97 CpG sites,
spanning  525 nt to +292 nt, relative to the transcriptional start site (+1). (B) Schema of the CpG island in hMLH1 containing 67 CpG sites, spanning  810
nt to +35 nt. Vertical bars denote the location of each CpG site. The graph shows the CpG island defined by Gardiner-Garden and Frommer of a region
greater than 200bp with a high GC content (grey line, number of CpG; black line, the frequency of C+G) and an observed/expected ratio for the
occurrence of CpG more than 0.6.
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stored at –201C. The whole CpG island in the MGMT promoter
region was amplified by nested PCR (Figure 2A). Primer sequences
and PCR conditions are presented in Table 1. The first round of
amplification was performed with 50ng of the bisulphite-treated
DNA. Then 1/1000th of the first PCR product was subjected
to the second round PCR. The size of the nested PCR product
was 835bp. The CpG island of hMLH1 was also amplified by
nested PCR (Figure 2B). The size of the nested PCR product was
815bp.
Cloning of PCR product and sequencing
The amplicons were cloned into the pSTBlue-1 Acceptor
TM Vector
(Novagen Inc., Madison, WI, USA) to transform competent JM109
cells (Wako Pure Chemical Industries, Ltd, Osaka, Japan). The
plasmid DNAs were amplified by colony PCR reactions (Table 1).
A total of 10 of the colony PCR products from each sample were
sequenced.
Statistical analysis
Differences among groups (normal liver tissues vs chronic
hepatitis, liver cirrhosis and HCC, or MGMT-negative vs -positive
HCCs) were tested by one-way analysis of variance (ANOVA).
Probability levels of o0.05 were considered statistically signifi-
cant.
RESULTS
Immunohistochemistry of MGMT and hMLH1
Immunohistochemical analysis was performed on normal liver,
noncancerous tissues, and HCCs to examine whether MGMT
and hMLH1 were expressed. Expression of these proteins was
detected in cells from normal liver, as well as in chronic hepatitis
and liver cirrhosis, including hepatocytes, bile duct cells,
vascular endothelial cells, smooth muscle, and so on (data not
shown). We used bile duct cells as an internal positive control
within the sections because these cells in cancerous regions also
commonly expressed MGMT and hMLH1 (Figure 1B, D). The
signals of MGMT-positive tumour cells were as intense as those of
the bile duct cells (Figure 1A), while those of MGMT-negative
tumour cells were virtually undetectable (Figure 1B). As for
hMLH1, signal intensity similar to those of bile duct cells was
detected in hMLH1-positive tumour cells (Figure 1C), but not in
hMLH1-negative tumours (Figure 1D). MGMT- and hMLH1-
negative tumours were 60.9% (28 out of 46) and 21.8% (10 out
of 46), respectively. Tumours lacking both proteins were
10.9% (5 out of 46) of all tumours. The results of immunohis-
tochemistry and the characteristics of patients with HCC are
shown in Table 2.
Methylation analysis of MGMT promoter region in HCCs,
noncancerous, and normal liver tissues
Next, we performed urea/bisulphite sequencing to investigate the
methylation status of MGMT and hMLH1 promoter region in
HCCs, noncancerous tissues, and normal liver. Prior to the study
of primary samples, to confirm that the nested PCR we used could
accurately reflect the methylation status of genomic DNA, we
performed PCR using DNA solutions containing methylated and
unmethylated genomic DNAs with different ratios. The methylated
and unmethylated DNAs were extracted from an MGMT-deficient
cell line, SW48 (Aquilina et al, 1998), in which the MGMT
promoter was fully methylated and an MGMT-proficient cell line,
HepG2 (Fritz and Kaina, 1992), in which the promoter was not
methylated at all. We found that the ratio of methylated to
unmethylated clones obtained from the nested PCR–cloning–
sequencing was consistent with the theoretical ratio (data not
shown).
The CpG island of MGMT including 97 CpG sites is shown in
Figure 2A. We examined the detailed methylation status of all CpG
sites by urea/bisulphite DNA sequencing in 46 HCCs (Figure 3A),
corresponding noncancerous tissues (Figure 3B), and 20 normal
liver tissues (Figure 3C). The methylation was somewhat observed
at the 50 border of the CpG island irrespective of cancerous or
noncancerous samples. These methylated CpGs in MGMT-positive
tumours, noncancerous tissues except for 4NC and 5NC, and
normal tissues never extended beyond the first nine CpGs.
However, a subset of MGMT-negative HCCs, 1C–15C, showed
that the methylation extended in the 30 direction beyond the first
nine CpGs. Tumour 1C showed all 97 hypermethylated CpG sites
in the island (data not shown). Other MGMT-negative tumours,
16C–28C, showed a similar extent of methylation to MGMT-
positive tumours and normal tissues.
From the point of view of hepatitis viral infection, the
methylation frequency at particular CpG sites in chronic hepatitis,
liver cirrhosis, and HCC was higher than that in normal liver with
statistical significance (Figure 4A). The frequency at those sites
increased along with pathological progression. Furthermore, the
methylation also extended towards downstream along with
pathological progression (Figure 4A). These data suggested that
hepatitis viral infection might be involved in methylation of the
MGMT promoter region. As for MGMT expression, MGMT-
negative tumours showed high frequency and widespread methy-
lation compared with MGMT-positive tumours and normal liver
(Figure 4B). There were significant statistical differences in the
methylation frequency at many CpG sites between MGMT-negative
and -positive HCCs. This result suggested that hypermethylation of
the MGMT promoter might play some role in the lack of MGMT
expression. Although we did not use the microdissection method,
our results might be of less estimation because of the existence of
nontumour DNA. If it is removed, further significant differences
could be obtained.
Methylation analysis of hMLH1 promoter region in HCCs,
noncancerous, and normal liver tissues
The CpG island of hMLH1 including 67 CpG sites is shown in
Figure 2B. All of the CpG sites were also analysed by urea/
bisulphite sequencing. In all, 10 hMLH1-negative HCCs were
detected by immunohistochemistry, and five of these showed
promoter hypermethylation (Figure 5). The methylation patterns
of these tumours were particular, that is, the middle portion of the
CpG island was methylated and the methylation frequency of each
CpG site in the region was approximately 60%. There was no
methylated CpG in hMLH1-positive HCCs, noncancerous regions,
and normal liver tissues (data not shown).
DISCUSSION
To date, it is thought that inactivation of the MGMT gene is
because of epigenetic changes such as DNA methylation (Esteller
et al, 1999, 2001) or some other unknown mechanisms because the
genetic change is uncommon. Although the methylation of MGMT
and hMLH1 promoter was analysed previously in HCCs, the
method used was mostly methylation-specific PCR (MSP) (Esteller
et al, 2001). No study has identified critical sites by a survey of
detailed methylation of the promoter regions of these genes. This is
the first study to examine the detailed CpG methylation status of
MGMT and hMLH1 promoter regions in HCCs, their adjacent
tissues, and normal liver tissues.
We compared MGMT-negative and -positive HCCs in order to
determine the critical CpG site for the MGMT silencing. A subset of
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yFigure 3 Detailed CpG (No. 1–29) methylation status of all analysed 97 CpGs within the MGMT promoter region in HCCs (A), adjacent tissues (B), and
normal liver (C). Each circle graph represents the percentage of methylated clones (number of methylated clones/10 analysed clones 100). Age in
parentheses (C).
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within CpGs No. 1–9 and a wide extent of methylation beyond
CpG No. 10. This evidence suggested that there were important
CpG(s) for gene silencing in the promoter region. It was known
that the MGMT enhancer, corresponding to our analysed CpGs No.
78–90, existed in the first intron. So far, the methylation of the
enhancer (Harris et al, 1994) has not been reported in liver
tumours by MSP (Esteller et al, 2001), and we also could not find
any methylated CpG in the enhancer, except for sample 1C. It was
reported that a single-site methylation upstream of the p53
promoter, not in the enhancer (Lozano and Levine, 1991), reduced
its expression during hepatocarcinogenesis in vivo (Pogribny et al,
2000). Therefore, it is possible that the methylation of specific CpG
site(s) in the MGMT promoter, aside from the enhancer, could
result in downregulation of MGMT gene expression in HCCs. Since
we found that some MGMT-negative tumours did not show the
very frequent and widespread methylation status, not only DNA
methylation but also histone deacetylation, chromatin remodel-
ling, post-transcriptional, and post-translational inactivation
might be correlated with the MGMT deficiency. MGMT is
converted to an inactive form after removing the methyl group
from O
6-methylguanine (Ishibashi et al, 1994). The inactivated
MGMT is not degraded but remains in an immunoreactive state in
normal cells (Liu et al, 2001), whereas it is degraded rapidly via the
ubiquitin proteolytic pathway in tumour cells (Srivenugopal et al,
1996; Liu et al, 2001). In the light of this, some tumours that
correspond to HCCs, 16C–28C, might be regarded as MGMT-
negative because of the rapid degradation of the inactive form,
although the gene might have been transcribed.
Our careful analysis revealed that both the frequency and extent
of MGMT methylation increased along with pathological progres-
sion. Although little is known of the link between hepatitis viral
infections and the methylation machinery of endogenous genes,
our findings intimated that CpG methylation of the MGMT gene
Figure 4 Frequency of methylation (%) of CpG sites (No. 1–29) in MGMT promoter region. (A) Methylation frequency of HCCs, liver cirrhosis, chronic
hepatitis with hepatitis viral infection, and normal liver tissues without infection were compared. *Po0.05 and **Po0.01 indicate the significant differences
of methylation frequency of each pathological stage vs that of normal liver at the CpG site. (B) Methylation frequencies of MGMT-negative (Mer( )) HCCs,
MGMT-positive (Mer(+)) HCCs, and normal liver tissues were compared. Frequency was calculated by (total number of methylated clones/10 analysed
clones case number at each CpG site) 100. *Po0.05, **Po0.01, and ***Po0.001 indicate the significant differences of methylation frequency of Mer
(+) HCC vs Mer ( ) HCC at CpG site.
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ywas associated with hepatitis viral infections. The levels of DNA
methyltransferase mRNA in chronic hepatitis, cirrhosis, and HCCs
associated with hepatitis viral infections increased compared with
those in normal liver tissues (Sun et al, 1997). Human
immunodeficiency virus induced the methylation of interferon g
(IFNG) through increased DNA methyltransferase activity (Miko-
vits et al, 1998). Therefore, CpG methylation of the MGMT
promoter could possibly be caused by elevated DNA methyltrans-
ferase activity in hepatocarcinogenesis. In contrast to the MGMT,
there was no methylation in hMLH1-positive HCCs, noncancerous,
and normal liver tissues with or without hepatitis viral infection
(data not shown), suggesting no relation between hMLH1
promoter methylation and viral infections. The methylation
mechanism for hMLH1 should be different from that for MGMT.
In the present study, the frequency of hMLH1 promoter
hypermethylation in HCCs was 10.9% (five out of 46) – half of
hMLH1-negative HCCs – and consistent with the previous finding,
10.0% (two out of 20) (Esteller et al, 2001). There was no promoter
methylation in the remaining five hMLH1-negative HCCs. In colon
cancer, gene mutations were found in hMLH1-negative tumours
without promoter hypermethylation (Cunningham et al, 1998).
Although we did not investigate the gene mutations in those HCCs,
genetic alterations would be involved in hMLH1-negative HCCs
without promoter hypermethylation.
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